{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:17:15Z","timestamp":1789823835494,"version":"4.0.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.mayocp.2012.03.006","type":"journal-article","created":{"date-parts":[[2012,6,4]],"date-time":"2012-06-04T16:11:21Z","timestamp":1338826281000},"page":"571-580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy"],"prefix":"10.1016","volume":"87","author":[{"given":"Stephen M.","family":"Ansell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O.","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.mayocp.2012.03.006_bib1","first-page":"1643","article-title":"PET\/CT in lymphoma: prospective study of enhanced full-dose PET\/CT versus unenhanced low-dose PET\/CT","volume":"47","author":"Rodriguez-Vigil","year":"2006","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.mayocp.2012.03.006_bib2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.nucmedbio.2009.03.009","article-title":"Comparison of 18F-FDG, 18F-FET and 18F-FLT for differentiation between tumor and inflammation in rats","volume":"36","author":"Lee","year":"2009","journal-title":"Nucl Med Biol"},{"issue":"7","key":"10.1016\/j.mayocp.2012.03.006_bib3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.crad.2010.03.012","article-title":"Non FDG PET","volume":"65","author":"Nanni","year":"2010","journal-title":"Clin Radiol"},{"issue":"12","key":"10.1016\/j.mayocp.2012.03.006_bib4","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1158\/1078-0432.CCR-06-3025","article-title":"Early response assessment using 3\u2032-deoxy-3\u2032-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma","volume":"13","author":"Herrmann","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.mayocp.2012.03.006_bib5","doi-asserted-by":"crossref","first-page":"430679","DOI":"10.1155\/2011\/430679","article-title":"Interim FDG-PET scan in Hodgkin's lymphoma: hopes and caveats","volume":"2011","author":"Andr\u00e9","year":"2011","journal-title":"Adv Hematol"},{"issue":"15","key":"10.1016\/j.mayocp.2012.03.006_bib6","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2009-11-253039","article-title":"The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma","volume":"115","author":"Dunleavy","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2012.03.006_bib7","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma","volume":"28","author":"Moskowitz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2012.03.006_bib8","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.mayocp.2012.03.006_bib9","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2967\/jnumed.107.042093","article-title":"Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis","volume":"48","author":"Lin","year":"2007","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.mayocp.2012.03.006_bib10","first-page":"1059","article-title":"Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials","volume":"47","author":"Shankar","year":"2006","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.mayocp.2012.03.006_bib11","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1007\/s00259-008-0874-2","article-title":"The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials [published correction appears in Eur J Nucl Med Mol Imaging. 2008;35(12):2342]","volume":"35","author":"Boellaard","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.mayocp.2012.03.006_bib12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","article-title":"FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0","volume":"37","author":"Boellaard","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.mayocp.2012.03.006_bib13","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.110.080556","article-title":"Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background","volume":"51","author":"Itti","year":"2010","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.mayocp.2012.03.006_bib14","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s00330-008-0866-4","article-title":"Semi-automated volumetric analysis of lymph node metastases in patients with malignant melanoma stage III\/IV\u2014a feasibility study","volume":"18","author":"Fabel","year":"2008","journal-title":"Eur Radiol"},{"issue":"8","key":"10.1016\/j.mayocp.2012.03.006_bib15","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the First International Workshop on Interim-PET-Scan in Lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.mayocp.2012.03.006_bib16","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/cncr.22807","volume":"110","author":"Tsukamoto","year":"2007","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.mayocp.2012.03.006_bib17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1080\/10428190701344915","article-title":"F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas","volume":"48","author":"Bishu","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.mayocp.2012.03.006_bib18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2214\/AJR.09.3665","article-title":"Characterization of T-cell lymphomas by FDG PET\/CT","volume":"195","author":"Feeney","year":"2010","journal-title":"AJR Am J Roentgenol"},{"issue":"10","key":"10.1016\/j.mayocp.2012.03.006_bib19","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/annonc\/mdm265","article-title":"FDG-PET in T-cell and NK-cell neoplasms","volume":"18","author":"Kako","year":"2007","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2012.03.006_bib20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/annonc\/mdq415","article-title":"18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T\/NK lymphomas: a study from the GOELAMS group","volume":"22","author":"Cahu","year":"2011","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.mayocp.2012.03.006_bib21","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2002-09-2778","article-title":"Utility of FDG-PET scanning in lymphoma by WHO classification","volume":"101","author":"Elstrom","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.mayocp.2012.03.006_bib22","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/cncr.24885","article-title":"Ability of integrated positron emission and computed tomography to detect significant colonic pathology: the experience of a tertiary cancer center","volume":"116","author":"Weston","year":"2010","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.mayocp.2012.03.006_bib23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.semradonc.2007.02.005","article-title":"2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas","volume":"17","author":"Specht","year":"2007","journal-title":"Semin Radiat Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2012.03.006_bib24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.mibio.2004.08.004","article-title":"Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography\/computed tomography hardware fusion for staging of patients with lymphoma","volume":"6","author":"Allen-Auerbach","year":"2004","journal-title":"Mol Imaging Biol"},{"issue":"3","key":"10.1016\/j.mayocp.2012.03.006_bib25","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1148\/radiol.2323030985","article-title":"Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging\u2014do we need contrast-enhanced CT?","volume":"232","author":"Schaefer","year":"2004","journal-title":"Radiology"},{"issue":"10","key":"10.1016\/j.mayocp.2012.03.006_bib26","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/annonc\/mdn282","article-title":"Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma","volume":"19","author":"Elstrom","year":"2008","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2012.03.006_bib27","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/1097-0142(20010301)91:5<889::AID-CNCR1078>3.0.CO;2-5","article-title":"2-(Fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma: a bicenter trial","volume":"91","author":"Buchmann","year":"2001","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.mayocp.2012.03.006_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.critrevonc.2004.05.007","article-title":"FDG-PET in the clinical management of Hodgkin lymphoma","volume":"52","author":"Hutchings","year":"2004","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.mayocp.2012.03.006_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2012.03.006_bib30","first-page":"266","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease","volume":"86","author":"Jerusalem","year":"2001","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.mayocp.2012.03.006_bib31","first-page":"115","article-title":"The role of FDG-PET imaging in the management of lymphoma","volume":"2","author":"Kostakoglu","year":"2004","journal-title":"Clin Adv Hematol Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2012.03.006_bib32","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1080\/028418602320405014","article-title":"Positron emission tomography for the staging of Hodgkin's lymphoma\u2014increasing the body of evidence in favor of the method","volume":"41","author":"Menzel","year":"2002","journal-title":"Acta Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2012.03.006_bib33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF02988618","article-title":"Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma","volume":"16","author":"Sasaki","year":"2002","journal-title":"Ann Nucl Med"},{"issue":"8","key":"10.1016\/j.mayocp.2012.03.006_bib34","first-page":"1139","article-title":"Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma","volume":"42","author":"Schoder","year":"2001","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.mayocp.2012.03.006_bib35","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood-2007-06-097238","article-title":"The role of FDG-PET scans in patients with lymphoma","volume":"110","author":"Seam","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2012.03.006_bib36","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00277-001-0390-y","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease","volume":"81","author":"Weihrauch","year":"2002","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.mayocp.2012.03.006_bib37","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0002-9343(01)01117-2","article-title":"Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma","volume":"112","author":"Wirth","year":"2002","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2012.03.006_bib38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2012.03.006_bib39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/blood.V94.2.429","article-title":"Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging","volume":"94","author":"Jerusalem","year":"1999","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.mayocp.2012.03.006_bib40","first-page":"1147","article-title":"18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas","volume":"11","author":"Mikhaeel","year":"2000","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2012.03.006_bib41","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2001.03147.x","article-title":"Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma","volume":"115","author":"Naumann","year":"2001","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.mayocp.2012.03.006_bib42","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.2001.19.2.414","article-title":"Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?","volume":"19","author":"Spaepen","year":"2001","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2012.03.006_bib43","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/annonc\/mdn671","article-title":"Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria","volume":"20","author":"Dupuis","year":"2009","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.mayocp.2012.03.006_bib44","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","article-title":"Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants","volume":"29","author":"Trotman","year":"2011","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.mayocp.2012.03.006_bib45","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.V116.21.765.765","article-title":"Dose-escalation with BEACOPP escalated is superior to ABVD in the combined-modality treatment of early unfavorable Hodgkin lymphoma: final analysis of the German Hodgkin Study Group (GHSG) HD14 trial","volume":"116","author":"Engert","year":"2010","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.mayocp.2012.03.006_bib46","article-title":"Limited-stage DLBCL patients with a negative PET scan following three cycles of R-CHOP have an excellent outcome following abbreviated immuno-chemotherapy alone","volume":"19","author":"Sehn","year":"2008","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"10.1016\/j.mayocp.2012.03.006_bib47","first-page":"152","article-title":"18FDG PET\/CT after intensified chemoimmunotherapy in diffuse large B-cell lymphoma (DLBCL), aged 18-65 years with AAIPI 2-3: Positive or indeterminate lesions have a low positive predictive value; A Nordic phase II substudy","volume":"22","author":"Holte","year":"2011","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2012.03.006_bib48","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1200\/JCO.2008.16.0861","article-title":"Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review","volume":"27","author":"Terasawa","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2012.03.006_bib49","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1002\/cncr.22276","article-title":"FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease","volume":"107","author":"Kostakoglu","year":"2006","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.mayocp.2012.03.006_bib50","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/annonc\/mdf256","article-title":"Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma","volume":"13","author":"Spaepen","year":"2002","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.mayocp.2012.03.006_bib51","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1182\/blood-2011-02-336990","article-title":"Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma","volume":"118","author":"Micallef","year":"2011","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.mayocp.2012.03.006_bib52","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1002\/cncr.25240","article-title":"Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis","volume":"116","author":"Lee","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.mayocp.2012.03.006_bib53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00277-010-1044-8","article-title":"The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma","volume":"90","author":"Goldschmidt","year":"2011","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.mayocp.2012.03.006_bib54","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00277-009-0752-4","article-title":"Role of 18FDG-PET\/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma","volume":"88","author":"Crocchiolo","year":"2009","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.mayocp.2012.03.006_bib55","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3109\/10428194.2010.547642","article-title":"Efficacy of routine surveillance with positron emission tomography\/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center","volume":"52","author":"El-Galaly","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.mayocp.2012.03.006_bib56","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00247-009-1434-z","article-title":"Estimated cumulative radiation dose from PET\/CT in children with malignancies: a 5-year retrospective review","volume":"40","author":"Chawla","year":"2010","journal-title":"Pediatr Radiol"},{"issue":"10","key":"10.1016\/j.mayocp.2012.03.006_bib57","first-page":"1790","article-title":"Predicting malignancy grade with PET in non-Hodgkin's lymphoma","volume":"36","author":"Rodriguez","year":"1995","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.mayocp.2012.03.006_bib58","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","author":"Noy","year":"2009","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2012.03.006_bib59","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/RLU.0b013e318203bb0e","article-title":"F-18 FDG PET\/CT for detection of malignant involvement of peripheral nerves: case series and literature review","volume":"36","author":"Bronstein","year":"2011","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1016\/j.mayocp.2012.03.006_bib60","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s00259-006-0295-z","article-title":"A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin","volume":"34","author":"Bleeker-Rovers","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.mayocp.2012.03.006_bib61","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejim.2010.09.015","article-title":"Diagnostic value of fluorine-18 fluorodeoxyglucose positron emission tomography\/computed tomography in patients with fever of unknown origin","volume":"22","author":"Sheng","year":"2011","journal-title":"Eur J Intern Med"},{"issue":"11","key":"10.1016\/j.mayocp.2012.03.006_bib62","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00259-009-1183-0","article-title":"Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?","volume":"36","author":"Salaun","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.mayocp.2012.03.006_bib63","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00259-008-1021-9","article-title":"Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate","volume":"36","author":"Paone","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1016\/j.mayocp.2012.03.006_bib64","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/MNM.0b013e3282eff2d5","article-title":"FDG PET in lymphoma: the need for standardization of interpretation","volume":"28","author":"Zijlstra","year":"2007","journal-title":"Nucl Med Commun"},{"issue":"16","key":"10.1016\/j.mayocp.2012.03.006_bib65","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO.2009.22.4089","article-title":"Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials","volume":"27","author":"Meignan","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.mayocp.2012.03.006_bib66","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","article-title":"Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma","volume":"37","author":"Barrington","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.mayocp.2012.03.006_bib67","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/annonc\/mdp071","article-title":"Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy","volume":"20","author":"Sher","year":"2009","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2012.03.006_bib68","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1182\/blood.V112.11.1453.1453","article-title":"Early FDG-PET scan predicts outcome in non-bulky limited stage Hodgkin lymphoma, but may not guide use of consolidative radiotherapy","volume":"112","author":"Barnes","year":"2008","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.mayocp.2012.03.006_bib69","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/blood.V116.21.766.766","article-title":"AHOD0031: a phase III study of dose-intensive therapy for intermediate risk Hodgkin lymphoma: a report from the Children's Oncology Group","volume":"116","author":"Friedman","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2012.03.006_bib70","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3816\/CLML.2010.n.056","article-title":"Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits?","volume":"10","author":"Shenoy","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619612003813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619612003813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T23:16:06Z","timestamp":1710458166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619612003813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0025619612003813"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2012.03.006","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2012.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}